Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aptose Biosciences, Inc. - Common Shares (NQ:APTO)

1.710 UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aptose Biosciences, Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 Next >
Get insights into the top gainers and losers of Tuesday's after-hours session.
The US market regular session of Tuesday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
Aptose Announces Reverse Share Split
From Aptose Biosciences, Inc.
Via GlobeNewswire
US Stocks Likely To Open Higher Amid Ukraine Peace Talk Hopes As Russian, American Officials Meet
U.S. stock futures rose on Tuesday following a mixed close on Friday after the Presidents' Day holiday on Monday. 
Via Benzinga
Why GCL Global Holdings Shares Are Trading Higher By Around 107%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility
From Aptose Biosciences, Inc.
Via GlobeNewswire
Thursday's pre-market session: top gainers and losers
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
These stocks are the most active in today's session
Discover the most active stocks in Wednesday's session. Stay informed about the stocks that are generating the most trading volume! 
Via Chartmill
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
TUS+VEN+AZA triplet has potential as frontline therapy to treat large, mutationally diverse populations of AML 
From Aptose Biosciences, Inc.
Via GlobeNewswire
Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket
Shares of Rumble Inc. 
Via Benzinga
Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Aptose Announces Positive Decision by Nasdaq Hearings Panel
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering
From Aptose Biosciences, Inc.
Via GlobeNewswire
Why Uxin Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results
 
Via Benzinga
Topics Stocks
Crude Oil Gains Over 1%; Ross Stores Earnings Top Views
 
Via Benzinga
Dow Jumps 300 Points; Gap Posts Upbeat Earnings
 
Via Benzinga
Topics Stocks
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering
From Aptose Biosciences, Inc.
Via GlobeNewswire
Why Elastic Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Reports Results for the Third Quarter 2024
Aptose and Hanmi Pharmaceutical Co-developing Triplet Therapy of Tuspetinib with Azacitidine and Venetoclax for Newly Diagnosed AML 
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Results from Special Meeting of Shareholders
From Aptose Biosciences, Inc.
Via GlobeNewswire
Why Zhibao Technology Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Hello Group, Zscaler And 3 Stocks To Watch Heading Into Tuesday
 
Via Benzinga
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
Proceeds to be used for development of lead compound tuspetinib in combination therapy as frontline treatment for newly diagnosed AML patients 
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Adjournment of its Special Meeting of Shareholders
From Aptose Biosciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.